Weekly Versus Tri-Weekly Cisplatin-Based Chemoradiotherapy in Locally Advanced Cervical Cancer

10 Mar 20265 min read0 viewsJournal Feed

GIST (Key Takeaways)

The standard treatment for locally advanced cervical cancer is cisplatin-based chemoradiotherapy; however, the optimal dose and dosing schedule of cisplatin remain debated.
The aim of this study was to compare the clinical outcomes of weekly cisplatin at 40 mg/m2 versus those of tri-weekly cisplatin at 75 mg/m2 during radiation in patients with locally advanced cervical cancer.

Clinical Editorial

ESMO Open published a clinical update in Oncology on 10 Mar 2026.

The item focuses on A randomized phase III clinical trial of weekly versus tri-weekly cisplatin-based chemoradiotherapy for locally advanced cervical cancer: results of the TACO (GCIG/KGOG 1027/THAI 2012) study.

Review the original article for the full source wording and details.